Palkion, Inc.™ is a privately held, early-stage company developing oral drugs that boost the body’s natural production of erythropoietin to treat anemia and other clinical indications. The company’s novel compounds are HIF-prolyl hydroxylase (HIF-PH) inhibitors, which stimulate red blood cell production to treat anemia as a first clinical indication. The use of an oral agent provides convenience and dosing flexibility, potentially reaching more patients than the current injectable products. Based in San Diego, the company was formed by ProQuest Investments and CrystalGenomics, Inc. in February 2008.